None
Quote | Outlook Therapeutics Inc. (NASDAQ:OTLK)
Last: | $7.09 |
---|---|
Change Percent: | 0.0% |
Open: | $7.41 |
Close: | $7.09 |
High: | $7.4646 |
Low: | $7.08 |
Volume: | 99,771 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Outlook Therapeutics Inc. (NASDAQ:OTLK)
2024-06-25 07:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Finding undervalued stocks to buy may greatly improve an investing portfolio’s ability to capture enormous long-term profits. This piece examines three inexpensive yet pote...
2024-06-13 17:22:01 ET Summary Outlook Therapeutics received a Complete Response Letter from the FDA in August 2023, causing a 74% drop in share price. Following a Type A meeting with the FDA in November 2023, Outlook agreed to conduct an additional clinical trial for ONS-5010. ...
Message Board Posts | Outlook Therapeutics Inc. (NASDAQ:OTLK)
Subject | By | Source | When |
---|---|---|---|
znewcar1: OTLK 21% v25,6M c1.79 f162M H1.85 morning pop got S@1.55 then sideways strong aft | znewcar1 | investorshangout | 02/04/2021 11:15:59 PM |
znewcar1: OTLK 27% v28,8M c1.47 f127M H1.65 got S@1.35 | znewcar1 | investorshangout | 02/03/2021 10:35:16 PM |
znewcar1: OTLK 20% v6,6M c1.050 f91,3M H1.09 S.92 | znewcar1 | investorshangout | 05/27/2020 8:59:40 PM |
znewcar1: OTLK 48% v6,0M c.875 f38M late day BO over .65 S@.7 then HOD.95 S.81 | znewcar1 | investorshangout | 01/03/2020 12:46:38 AM |
znewcar1: OTLK 53% v6,1M c1.59 f28,M H 1.74 After hour gap and fad then @10 BO1.19 H1.74 S1.50 and e | znewcar1 | investorshangout | 12/03/2019 9:15:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Company Name:
OTLK Stock Symbol:
NASDAQ Market:
Outlook Therapeutics Inc. Website:
Live video webcast on Tuesday, June 18 th at 12:00 PM ET ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; be...
LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMD European Commission decision applies automatically to all 27 EU Member States and, within 30 days, also to Iceland, ...